X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/pulmatrix-announces-stopping-the-pur1900-phase-2b-study-patient-enrollment-and-closing-the-study-in-agreement-with-partner-cipla-to-preserve-cash-and-facilitate-pursuit-of-strategic-alternatives-302027934.html
https://www.prnewswire.com/news-releases/pulmatrix-announces-third-quarter-2023-financial-results-and-provides-corporate-update-301982988.html
https://www.prnewswire.com/news-releases/pulmatrix-announces-fda-acceptance-of-ind-application-for-pur3100-to-treat-acute-migraine-301931879.html
https://www.prnewswire.com/news-releases/pulmatrix-announces-publication-on-physiologically-based-pharmacokinetic-modelling-of-potential-drug-drug-interactions-with-pur1900-orally-inhaled-itraconazole-301907549.html
https://www.prnewswire.com/news-releases/pulmatrix-announces-second-quarter-2023-financial-results-and-provides-corporate-update-301897520.html
https://www.prnewswire.com/news-releases/pulmatrix-announces-submission-of-ind-application-to-fda-to-initiate-a-phase-2-trial-of-investigational-drug-pur3100-to-treat-acute-migraine-301873837.html
https://www.prnewswire.com/news-releases/pulmatrix-presents-pur3100-phase-1-data-at-the-65th-annual-meeting-of-the-american-headache-society-301852038.html
https://www.prnewswire.com/news-releases/pulmatrix-announces-first-quarter-2023-financial-results-and-provides-corporate-update-301823032.html
https://www.prnewswire.com/news-releases/pulmatrix-announces-year-end-and-q4-financial-2022-results-and-provides-corporate-update-301785409.html
https://www.prnewswire.com/news-releases/pulmatrix-to-host-key-opinion-leader-webinar-pur3100-for-the-treatment-of-acute-migraine-unlocking-the-potential-of-dhe-treatment-301729996.html
Market Place
Share 
